In the Hu-HSC model of EBV-associated lymphoma, the combination of PD-1 and CTLA-4 inhibitors can effectively inhibit the growth of EBV-induced diffuse large B-cell lymphoma and the anti-tumor effect is better than that of monotherapy [156,157]. Here, CTLA4 is linked to neoplasm.